Back

Tafamidis in patients with amyloid cardiomyopathy: a systematic review and meta-analysis of 14 studies.

1 September 2025 (12:30 - 13:15)
Organised by: Logo
Congress Presentation Part of: New perspectives in cardiology (4) - Molecular mechanisms and genetic insights in cardiomyopathies Cardiomyopathies ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Doctor Mostafa Ahmad Helmy Mohammad Nassar

Tanta (Egypt)

9 More presentations in this session

Presentation thumbnail
Presentation thumbnail
Doctor X. Tan (Suzhou, CN)
Abstract Slides Video
Presentation thumbnail
Doctor H. Tseng (Hsinchu, TW)
Abstract Slides Video
Presentation thumbnail
Doctor Y. Devaux (Luxembourg, LU)
Abstract Slides Video
Presentation thumbnail
Associate Professor K. Pilichou (Padova, IT)
Abstract

Access the full session

Session thumbnail
New perspectives in cardiology (4) - Molecular mechanisms and genetic insights in cardiomyopathies

The Event

Event poster

ESC Congress 2025

1 September 2025 12:30 CET
You may be interested in
thumbnail
Congress Presentation
Relative efficacy of tafamidis, acoramidis, patisiran and vutrisiran in patients with transthyretin cardiac amyloidosis: a network meta-analysis
thumbnail
Congress Presentation
Amyloid-specific medication in transthyretin amyloid cardiomyopathy: a systemic review and meta-analysis.
thumbnail
Congress Presentation
Tafamidis for the treatment of transthyretin cardiac amyloidosis (ATTR-CM) - Real-world data from a tertiary center.

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources